{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Protalix BioTherapeutics, Inc."},"Symbol":{"label":"Symbol","value":"PLX"},"Address":{"label":"Address","value":"2 UNIVERSITY PLAZA,SUITE 100, HACKENSACK, New Jersey, 07601, United States"},"Phone":{"label":"Phone","value":"+1 201 696-9345"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Middle East"},"CompanyDescription":{"label":"Company Description","value":"Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis.The company's primary sources of revenues include its sales of taliglucerase alfa in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement."},"CompanyUrl":{"label":"Company Url","value":"https://www.protalix.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Dror Bashan","title":"President, Chief Executive Officer & Director"},{"name":"Yael Hayon","title":"Vice President-Research & Development"},{"name":"Yaron Naos","title":"Senior Vice President-Operations"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}